Literature DB >> 22933333

Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.

Amel Sebaa1, Lionel Ades, Fanny Baran-Marzack, Marie-Joelle Mozziconacci, Dominique Penther, Sophie Dobbelstein, Aspasia Stamatoullas, Christian Récher, Thomas Prebet, Soraya Moulessehoul, Pierre Fenaux, Virginie Eclache.   

Abstract

TP53 mutations are frequent in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) with complex karyotype that include del(5q) and are often associated with deletion of 17p. They have also recently been observed in MDS with isolated del(5q). We assessed the incidence of 17p deletion detected by fluorescence in situ hybridization (FISH) and of TP53 mutations detected by direct sequencing and their correlation and prognostic value in 26 MDS and 17 AML with del(5q). In the 20 cases with isolated del(5q) or one additional abnormality, no 17p deletion was found and 3 of the 18 cases analyzed (17%) had TP53 mutation. In the 23 patients with complex karyotype, 17p deletion was suspected by conventional cytogenetics in 15 cases and confirmed by FISH in 10 of them, while TP53 mutation was found in 8 of the 15 patients tested (53%), only five of whom had 17p deletion. In the whole patient series, TP53 mutations were associated with shorter survival (P = 0.07). We confirm the existence of TP53 mutations in 17% of MDS with isolated del(5q). In patients with del(5q) and complex karyotype, FISH and direct sequencing are complementary techniques to analyze TP53 abnormalities. Our findings also suggest that sequencing of the TP53 gene should be included in the study of patients with del(5q) as a single abnormality or in complex karyotype before lenalidomide treatment.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22933333     DOI: 10.1002/gcc.21993

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  26 in total

1.  What lies beyond del(5q) in myelodysplastic syndrome?

Authors:  Vera Adema; Rafael Bejar
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

2.  Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.

Authors:  Uta Oelschlaegel; Theresia M Westers; Brigitte Mohr; Michael Kramer; Stefani Parmentier; Katja Sockel; Christian Thiede; Martin Bornhäuser; Gerhard Ehninger; Arjan A van de Loosdrecht; Uwe Platzbecker
Journal:  Haematologica       Date:  2014-11-25       Impact factor: 9.941

Review 3.  Patterns of mutations in TP53 mutated AML.

Authors:  John S Welch
Journal:  Best Pract Res Clin Haematol       Date:  2018-09-20       Impact factor: 3.020

4.  Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.

Authors:  Marta Fernandez-Mercado; Adam Burns; Andrea Pellagatti; Aristoteles Giagounidis; Ulrich Germing; Xabier Agirre; Felipe Prosper; Carlo Aul; Sally Killick; James S Wainscoat; Anna Schuh; Jacqueline Boultwood
Journal:  Haematologica       Date:  2013-07-05       Impact factor: 9.941

Review 5.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

6.  Myelodysplastic syndromes, version 2.2015.

Authors:  Peter L Greenberg; Richard M Stone; Rafael Bejar; John M Bennett; Clara D Bloomfield; Uma Borate; Carlos M De Castro; H Joachim Deeg; Amy E DeZern; Amir T Fathi; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Elizabeth A Griffiths; David Head; Virginia Klimek; Rami Komrokji; Lisa A Kujawski; Lori J Maness; Margaret R O'Donnell; Daniel A Pollyea; Bart Scott; Paul J Shami; Brady L Stein; Peter Westervelt; Benton Wheeler; Dorothy A Shead; Courtney Smith
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

Review 7.  [Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification].

Authors:  A H Schmitt-Graeff; M J Müller; P Fisch
Journal:  Pathologe       Date:  2013-02       Impact factor: 1.011

Review 8.  Stopping higher-risk myelodysplastic syndrome in its tracks.

Authors:  Daniel A Pollyea; Jonathan A Gutman
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

9.  Clinical and genetic predictors of prognosis in myelodysplastic syndromes.

Authors:  Rafael Bejar
Journal:  Haematologica       Date:  2014-06       Impact factor: 9.941

10.  Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.

Authors:  Guillermo Montalban-Bravo; Rashmi Kanagal-Shamanna; Christopher B Benton; Caleb A Class; Kelly S Chien; Koji Sasaki; Kiran Naqvi; Yesid Alvarado; Tapan M Kadia; Farhad Ravandi; Naval Daver; Koichi Takahashi; Elias Jabbour; Gautham Borthakur; Naveen Pemmaraju; Marina Konopleva; Kelly A Soltysiak; Sherry R Pierce; Carlos E Bueso-Ramos; Keyur P Patel; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Blood Adv       Date:  2020-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.